Company
Headquarters: Wuhan, China
CN¥2.80 Billion
CNY as of July 1, 2024
US$385.6 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye, an acyclovir dispensable tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository drug; Xunkeyuan, a tinidazole suppository drug; and Shufu, a nimodipine sustained release tablets. The company also provides measles virus and rubella virus nucleic acid detection kit; mycoplasma isolation and identification kit and culture tube; bacterial vaginosis rapid detection kit; measles virus IgG antibody detection kit; and coronavirus N-protein detection kit. In addition, it offers Lopinavir and Ritonavir APIs; and intermediates. The company offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Wuhan Hiteck Biological Pharma Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300683 wb_incandescent